A proposed clinical scoring system for initiation of lenvatinib treatment in radioiodine-refractory thyroid cancer patients.

MLA

Fukuda, Naoki, et al. “A Proposed Clinical Scoring System for Initiation of Lenvatinib Treatment in Radioiodine-Refractory Thyroid Cancer Patients.” Endocrine (1355008X), vol. 76, no. 1, Apr. 2022, pp. 70–77. EBSCOhost, https://doi.org/10.1007/s12020-021-02963-z.

APA

Fukuda, N., Toda, K., Udagawa, S., Ohmoto, A., Oki, R., Suto, H., Wang, X., Hayashi, N., Urasaki, T., Sato, Y., Nakano, K., Ono, M., Tomomatsu, J., Mitani, H., & Takahashi, S. (2022). A proposed clinical scoring system for initiation of lenvatinib treatment in radioiodine-refractory thyroid cancer patients. Endocrine (1355008X), 76(1), 70–77. https://doi.org/10.1007/s12020-021-02963-z

Chicago

Fukuda, Naoki, Kazuhisa Toda, Shohei Udagawa, Akihiro Ohmoto, Ryosuke Oki, Hirotaka Suto, Xiaofei Wang, et al. 2022. “A Proposed Clinical Scoring System for Initiation of Lenvatinib Treatment in Radioiodine-Refractory Thyroid Cancer Patients.” Endocrine (1355008X) 76 (1): 70–77. doi:10.1007/s12020-021-02963-z.